Fludarabine Phosphate Clinical Trials

• Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL
  ClinicalTrials.gov Identifier: NCT00185445 - Active, not recruiting
  Non Hodgkin Lymphoma
  
• Safety and Effectiveness of Combretastatin A-4 Phosphate Combined with Chemotherapy in Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00113438 - Active, not recruiting
  Cancer; Tumor
  
• Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed or Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome
  ClinicalTrials.gov Identifier: NCT00005593 - Active, not recruiting
  Leukemia
  
• Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
  ClinicalTrials.gov Identifier: NCT00577161 - Recruiting
  Non-Hodgkin's Lymphoma
  
• Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00003768 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
  ClinicalTrials.gov Identifier: NCT00060242 - Active, not recruiting
  anaplastic thyroid cancer; recurrent thyroid cancer
  
• Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00003553 - Recruiting
  Kidney Cancer
  
• Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
  ClinicalTrials.gov Identifier: NCT00074178 - Active, not recruiting
  primary central nervous system lymphoma; intraocular lymphoma
  
• Peripheral Stem Cell Transplant and White Blood Cell Transfusions in Treating Patients With Refractory Metastatic Solid Tumors
  ClinicalTrials.gov Identifier: NCT00003839 - Recruiting
  Cancer
  
• Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders
  ClinicalTrials.gov Identifier: NCT00010361 - Active, not recruiting
  Metabolism, Inborn Errors; Granulomatous Disease, Chronic
  
• A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia
  ClinicalTrials.gov Identifier: NCT00220311 - Completed
  Chronic Lymphocytic Leukemia
  
• Genasense™ (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects with Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00078234 - Active, not recruiting
  Chronic Lymphocytic Leukemia
  
• Autograft Versus Calcium Phosphate Macroporous Bioceramics as Bone Substitute for Tibial Valgus Osteotomy
  ClinicalTrials.gov Identifier: NCT00200603 - Active, not recruiting
  Osteoarthritis of the Knee
  
• Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin''s Lymphoma
  ClinicalTrials.gov Identifier: NCT00117156 - Active, not recruiting
  Lymphoma, Non-Hodgkin; MALT Lymphoma
  
• Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease
  ClinicalTrials.gov Identifier: NCT00004194 - Active, not recruiting
  Graft Versus Host Disease
  
• Fludarabine, Total-body Irradiation, Donor Peripheral Stem Cell Transplantation, and Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
  ClinicalTrials.gov Identifier: NCT00005799 - Active, not recruiting
  Leukemia; Renal Cell Cancer; Lymphoma; Eye Cancer; Kidney Cancer
  
• Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00138229 - Active, not recruiting
  Recurrent Melanoma; Stage IV Melanoma
  
• Busulfan and Fludarabine in Patients With AML and MDS
  ClinicalTrials.gov Identifier: NCT00502905 - Active, not recruiting
  Leukemia
  
• Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00024440 - Active, not recruiting
  refractory chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
  
• Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00193271 - Active, not recruiting
  Prostate Cancer
  
• Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00002779 - Active, not recruiting
  Lymphoma; Lymphoma, Small Lymphocytic; Lymphoma, Mantle-Cell; Waldenstrom's Macroglobulinemia; Lymphoma, Mucosa-Associated Lymphoid Tissue
  
• Flavopiridol, Fludarabine, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
  ClinicalTrials.gov Identifier: NCT00058227 - Active, not recruiting
  adult non-Hodgkin's lymphoma; Chronic Lymphocytic Leukemia; Hairy Cell Leukemia
  
• Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00086775 - Active, not recruiting
  refractory chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
  
• Phosphate Intake's Effect on the Skeletal System - Pilot
  ClinicalTrials.gov Identifier: NCT00187629 - Recruiting
  Healthy; Kidney Failure, Chronic
  
• Alemtuzumab/Fludarabine for Relapsed/Refractory B-CLL
  ClinicalTrials.gov Identifier: NCT00206726 - Active, not recruiting
  Leukemia, Lymphocytic, Chronic, B-Cell
  
• Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  ClinicalTrials.gov Identifier: NCT00143065 - Active, not recruiting
  Lymphoma, Small Lymphocytic; Lymphocytic Leukemia, Chronic
  
• Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
  ClinicalTrials.gov Identifier: NCT00452374 - Active, not recruiting
  Leukemia
  
• The Effects of Dietary Phosphate Intake on Calciotropic Hormones and FGF23.
  ClinicalTrials.gov Identifier: NCT00305279 - Recruiting
  Healthy; Kidney Failure, Chronic
  
• Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
  ClinicalTrials.gov Identifier: NCT00506857 - Active, not recruiting
  Hematologic Malignancies
  
• A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women
  ClinicalTrials.gov Identifier: NCT00532077 - Recruiting
  Osteoporosis
  
• 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Fludarabine and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia That Did Not Respond to Fludarabine
  ClinicalTrials.gov Identifier: NCT00098488 - Recruiting
  B-cell Chronic Lymphocytic Leukemia; refractory chronic lymphocytic leukemia; Prolymphocytic Leukemia
  
• Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Did Not Respond to Fludarabine
  ClinicalTrials.gov Identifier: NCT00104858 - Recruiting
  refractory chronic lymphocytic leukemia; recurrent small lymphocytic lymphoma; B-cell Chronic Lymphocytic Leukemia; ...
  
• Efficacy of Phosphate Binding in Healthy Volunteers: Chewed vs. Crushed Lanthanum Carbonate
  ClinicalTrials.gov Identifier: NCT00458289 - Recruiting
  Hyperphosphatemia in Chronic Kidney Disease
  
• The Effects of Post-Conditioning and Administration of Vitamin C on Intramuscular High Energy Phosphate Levels
  ClinicalTrials.gov Identifier: NCT00534924 - Recruiting
  Ischemia Reperfusion Injury
  
• Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00093522 - Active, not recruiting
  recurrent renal cell cancer; Stage IV Renal Cell Cancer
  
• Fludarabine and Melphalan Followed by Tacrolimus and Methotrexate in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Relapsed Lymphoma
  ClinicalTrials.gov Identifier: NCT00121186 - Active, not recruiting
  adult Hodgkin''s lymphoma; adult non-Hodgkin''s lymphoma
  
• Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Lymphoma
  ClinicalTrials.gov Identifier: NCT00006252 - Active, not recruiting
  adult non-Hodgkin's lymphoma; Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia
  
• Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00085423 - Recruiting
  Recurrent Melanoma; Stage IV Melanoma
  
• Phase II Study to Evaluate the Combination of Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients with B-CLL
  ClinicalTrials.gov Identifier: NCT00147901 - Recruiting
  B-cell Chronic Lymphocytic Leukemia
  
• Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate With or Without Sodium Thiosulfate in Treating Patients With High-Grade Glioma
  ClinicalTrials.gov Identifier: NCT00075387 - Recruiting
  adult anaplastic astrocytoma; adult anaplastic ependymoma; adult anaplastic oligodendroglioma; adult brain tumor; adult glioblastoma; ...
  
• Fludarabine Followed by Campath-1H in Treating Patients With Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00004857 - Active, not recruiting
  stage II chronic lymphocytic leukemia; stage IV chronic lymphocytic leukemia; stage I chronic lymphocytic leukemia; ...
  
• Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00276848 - Active, not recruiting
  Leukemia
  
• Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00281931 - Active, not recruiting
  Leukemia
  
• Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
  ClinicalTrials.gov Identifier: NCT00577993 - Active, not recruiting
  Lymphoma
  
• Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma
  ClinicalTrials.gov Identifier: NCT00317759 - Active, not recruiting
  Melanoma (Skin)
  
• Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine
  ClinicalTrials.gov Identifier: NCT00274976 - Active, not recruiting
  Leukemia
  
• Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00281918 - Active, not recruiting
  Leukemia
  
• Total Body Irradiation, Thiotepa, and Fludarabine Followed By A Donor Peripheral Blood Stem Cell Transplant in Treating Young Patients With Hematologic Cancer
  ClinicalTrials.gov Identifier: NCT00112567 - Active, not recruiting
  childhood acute lymphoblastic leukemia; childhood acute myeloid leukemia and other myeloid malignancies; Chronic Myelogenous Leukemia; ...
  
• Chemotherapy and Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Disease or Hematologic Cancer
  ClinicalTrials.gov Identifier: NCT00003838 - Recruiting
  Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; ...
  
• Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00003659 - Active, not recruiting
  stage II chronic lymphocytic leukemia; stage III chronic lymphocytic leukemia; stage IV chronic lymphocytic leukemia
  
• Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00003248 - Active, not recruiting
  stage II chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia; stage IV chronic lymphocytic leukemia; ...
  
• Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00262795 - Active, not recruiting
  Leukemia
  
• A Randomized Controlled Trial Comparing Picosalax and Oral Sodium Phosphate for Colon Cleansing Prior to Colonoscopy
  ClinicalTrials.gov Identifier: NCT00410215 - Recruiting
  Colonoscopy
  
• Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00062036 - Active, not recruiting
  Melanoma (Skin)
  
• Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer
  ClinicalTrials.gov Identifier: NCT00363454 - Recruiting
  Cancer
  
• Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
  ClinicalTrials.gov Identifier: NCT00008151 - Active, not recruiting
  Previously Treated Myelodysplastic Syndrome; secondary myelodysplastic syndrome; recurrent adult acute myeloid leukemia; ...
  
• Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
  ClinicalTrials.gov Identifier: NCT00044954 - Active, not recruiting
  Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm
  
• Fludarabine and Rituximab Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00098670 - Active, not recruiting
  B-cell Chronic Lymphocytic Leukemia; stage I chronic lymphocytic leukemia; stage II chronic lymphocytic leukemia; ...
  
• Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia
  ClinicalTrials.gov Identifier: NCT00281983 - Active, not recruiting
  Leukemia; Lymphoma
  
• Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
  ClinicalTrials.gov Identifier: NCT00073879 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00091104 - Active, not recruiting
  Melanoma (Skin)
  
• Rituximab, Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Sodium Thiosulfate and Cytarabine in Treating Patients With Refractory or Recurrent Primary CNS Lymphoma
  ClinicalTrials.gov Identifier: NCT00074165 - Recruiting
  Drug Toxicity; Thrombocytopenia; intraocular lymphoma; primary central nervous system lymphoma
  
• Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00049075 - Active, not recruiting
  B-cell Chronic Lymphocytic Leukemia; stage I chronic lymphocytic leukemia; stage II chronic lymphocytic leukemia; ...
  
• Fludarabine and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00119340 - Active, not recruiting
  accelerated phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia; relapsing chronic myelogenous leukemia; ...
  
• A Study of an Investigational Study Drug for Type 2 Diabetes Mellitus
  ClinicalTrials.gov Identifier: NCT00127192 - Active, not recruiting
  Type2 Diabetes Mellitus
  
• Chemotherapy Consisting of Fludarabine and Cyclophosphamide Followed By White Blood Cell Infusion, Vaccine Therapy, and Aldesleukin in Treating Patients With Recurrent or Refractory Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00084500 - Active, not recruiting
  Melanoma (Skin)
  
• Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00096382 - Active, not recruiting
  Melanoma (Skin)
  
• Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00003764 - Active, not recruiting
  stage 0 chronic lymphocytic leukemia; stage I chronic lymphocytic leukemia; stage II chronic lymphocytic leukemia; ...
  
• Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  ClinicalTrials.gov Identifier: NCT00193466 - Active, not recruiting
  Non-Hodgkins Lymphoma
  
• Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients
  ClinicalTrials.gov Identifier: NCT00382694 - Active, not recruiting
  Multiple Myeloma
  
• Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00243009 - Active, not recruiting
  Kidney Cancer
  
• Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
  ClinicalTrials.gov Identifier: NCT00004114 - Active, not recruiting
  Leukemia; Lymphoma
  
• A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00218205 - Recruiting
  Prostate Cancer
  
• Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
  ClinicalTrials.gov Identifier: NCT00301951 - Active, not recruiting
  Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
  
• Chemotherapy in Treating Patients With Solid Tumors
  ClinicalTrials.gov Identifier: NCT00003698 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Osteoconductor Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects
  ClinicalTrials.gov Identifier: NCT00206791 - Recruiting
  Bone Defect
  
• Imatinib Mesylate, Busulfan, Fludarabine, and ATG for CML Patients
  ClinicalTrials.gov Identifier: NCT00499889 - Recruiting
  Leukemia
  
• Radiation Therapy and Fludarabine Followed by Donor Peripheral Stem Cell Transplantation, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Hematologic Cancer
  ClinicalTrials.gov Identifier: NCT00014235 - Active, not recruiting
  childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; hematopoietic and lymphoid cancer
  
• Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00262782 - Active, not recruiting
  Leukemia
  
• Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF and Rituximab
  ClinicalTrials.gov Identifier: NCT00208975 - Recruiting
  Lymphoma
  
• Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients
  ClinicalTrials.gov Identifier: NCT00410163 - Recruiting
  B-Cell Chronic Lymphocytic Leukemia
  
• Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00091143 - Recruiting
  Recurrent Melanoma; stage III melanoma; Stage IV Melanoma
  
• Fludarabine Plus Cyclophosphamide Followed by Zevalin in Non-Follicular Indolent Lymphomas Refractory or Relapsed
  ClinicalTrials.gov Identifier: NCT00354822 - Recruiting
  Lymphoma, Non-Hodgkin
  
• Obatoclax Mesylate, Fludarabine and Rituximab in Previously Treated Patients With B-CLL
  ClinicalTrials.gov Identifier: NCT00574938 - Recruiting
  Chronic Lymphocytic Leukemia
  
• Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects with End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood
  ClinicalTrials.gov Identifier: NCT00150566 - Completed
  Kidney Failure, Chronic
  
• Bortezomib and Fludarabine in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00068315 - Recruiting
  adult non-Hodgkin's lymphoma; Chronic Lymphocytic Leukemia; indolent or aggressive adult non-Hodgkin's lymphoma
  
• Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, and Radiation Therapy in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Relapsed Or Refractory Non-Hodgkin''s Lymphoma
  ClinicalTrials.gov Identifier: NCT00119392 - Recruiting
  adult non-Hodgkin''s lymphoma
  
• Iodine I 131 Tositumomab and Fludarabine in Treating Older Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00110071 - Recruiting
  adult non-Hodgkin's lymphoma; indolent or aggressive adult non-Hodgkin's lymphoma
  
• Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML
  ClinicalTrials.gov Identifier: NCT00529880 - Recruiting
  Acute Myeloid Leukemia
  
• Fludarabine, Alemtuzumab, and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Donor White Blood Cell Infusion in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00416884 - Active, not recruiting
  Leukemia
  
• Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease
  ClinicalTrials.gov Identifier: NCT00438932 - Recruiting
  Chronic Kidney Disease
  
• Comparison of Fludarabine Plus Total-body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00041288 - Active, not recruiting
  Waldenstrom's Macroglobulinemia; refractory chronic lymphocytic leukemia; recurrent grade I follicular small cleaved cell lymphoma; ...
  
• Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
  ClinicalTrials.gov Identifier: NCT00004145 - Active, not recruiting
  Leukemia; Lymphoma; Multiple Myeloma
  
• Total-Body Irradiation With Or Without Fludarabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
  ClinicalTrials.gov Identifier: NCT00075478 - Recruiting
  childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; plasma cell neoplasm
  
• Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or Larynx
  ClinicalTrials.gov Identifier: NCT00004246 - Active, not recruiting
  stage IV squamous cell carcinoma of the lip and oral cavity; stage IVA squamous cell carcinoma of the nasopharynx; ...
  
• Adding Phosphorus to Osteoporosis Drug Treatment
  ClinicalTrials.gov Identifier: NCT00074711 - Recruiting
  Osteoporosis; Osteopenia
  
• Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00096018 - Recruiting
  stage I chronic lymphocytic leukemia; stage II chronic lymphocytic leukemia; stage III chronic lymphocytic leukemia; ...
  
• Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00389506 - Recruiting
  Lymphoma
  
• Fludarabine, Cyclophosphamide, and Vaccine Therapy in Treating Patients With Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00509496 - Recruiting
  Melanoma (Skin)
  
• Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
  ClinicalTrials.gov Identifier: NCT00572897 - Recruiting
  Myelofibrosis